A combination of fenofibrate with a liver-targeted acetyl-CoA carboxylase inhibitor enhances efficacy while reversing plasma triglyceride increases in a murine model of NASH

被引：0
|
作者：
Bates, Jamie [1 ]
Vijayakumar, Archana [1 ]
Hollenback, David [1 ]
Kusam, Saritha [1 ]
Burri, Harini [1 ]
Breckenridge, David G. [1 ]
机构：
[1] Gilead Sci Inc, Biol, 353 Lakeside Dr, Foster City, CA 94404 USA
来源：
JOURNAL OF HEPATOLOGY | 2019年 / 70卷 / 01期
关键词：
D O I：
10.1016/S0618-8278(19)31029-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
FRI-284
引用
收藏
页码：E520 / E521
页数：2
相关论文
共 14 条
  • [1] A liver-targeted acetyl CoA carboxylase inhibitor reduces hepatic steatosis and liver injury in a murine model of NASH
    Bates, J.
    Brockett, R.
    Mikaelian, I.
    Wang, T.
    Ray, A.
    Tumas, D.
    Breckenridge, D.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S430 - S430
  • [2] A Liver-Targeted Acetyl-CoA Carboxylase Inhibitor Increases Fatty Acid Oxidation, Improves Mitochondrial Function and Reduces Bile Acids and Oxidative Stress in a Murine Model of NASH
    Bates, Jamie
    Hollenback, David
    Liu, Kathy
    Wang, Ting
    Wong, Kari E.
    Ray, Adrian S.
    Breckenridge, David
    HEPATOLOGY, 2017, 66 : 1084A - 1084A
  • [3] GS-0976, a Liver-Targeted Acetyl-CoA Carboxylase (ACC) Inhibitor, Reduces Plasma Acylcarnitines in Patients with Nonalcoholic Steatohepatitis (NASH)
    Charlton, Michael R.
    Lai, Michelle
    Noureddin, Mazen
    Tarrant, Jacqueline M.
    Wang, Lulu
    Tuan Nguyen
    McColgan, Bryan John
    Chung, Chuhan
    Patterson, Scott D.
    Myers, Robert P.
    Mantry, Parvez
    Ruane, Peter J.
    Loomba, Rohit
    HEPATOLOGY, 2018, 68 : 992A - 993A
  • [4] Concentration-QT analysis of firsocostat, a liver-targeted acetyl-coa carboxylase inhibitor
    Hsueh, Chia-Hsiang
    Yue, Mun Sang
    Millward, Victoria
    Huber, Darren
    Chung, Chuhan
    Myers, Robert
    Weber, Elijah
    Nelson, Cara
    JOURNAL OF HEPATOLOGY, 2020, 73 : S445 - S445
  • [5] Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate
    Dandan, Mohamad
    Han, Julia
    Mann, Sabrina
    Kim, Rachael
    Li, Kelvin
    Mohammed, Hussein
    Chuang, Jen-Chieh
    Zhu, Kaiyi
    Billin, Andrew N.
    Huss, Ryan S.
    Chung, Chuhan
    Myers, Robert P.
    Hellerstein, Marc
    JOURNAL OF LIPID RESEARCH, 2023, 64 (03)
  • [6] A PHASE 1 MASS BALANCE STUDY OF FIRSOCOSTAT, A LIVER-TARGETED ACETYL-COA CARBOXYLASE INHIBITOR.
    Hsueh, C.
    Qin, A.
    West, S.
    Chung, C.
    Othman, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S24 - S24
  • [7] Pharmacokinetics, mass balance, metabolism, and excretion of the liver-targeted acetyl-CoA carboxylase inhibitor PF-05221304 (clesacostat) in humans
    Ryder, Tim F.
    Bergman, Arthur
    King-Ahmad, Amanda
    Amin, Neeta B.
    Lall, Manjinder S.
    Ballard, T. Eric
    Kalgutkar, Amit S.
    XENOBIOTICA, 2022, 52 (03) : 240 - 253
  • [8] Combination of an acetyl CoA carboxylase inhibitor with therapeutics that promote fatty acid oxidation moderately improves efficacy in a preclinical NASH model
    Vijayakumar, Archana
    Olson, Isabel
    Mahadevan, Sangeetha
    Wang, Ting
    Zaboli, Shiva
    Toteva, Maria
    Trevaskis, James
    Breckenridge, David
    Bates, Jamie
    JOURNAL OF HEPATOLOGY, 2020, 73 : S509 - S509
  • [9] Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Firsocostat, a Liver-Targeted Inhibitor of Acetyl-CoA Carboxylase
    Weber, Elijah J.
    Younis, Islam R.
    Nelson, Cara
    Qin, Ann R.
    Watkins, Timothy R.
    Othman, Ahmed A.
    CLINICAL PHARMACOKINETICS, 2024, 63 (10) : 1423 - 1434
  • [10] Combination of an acetyl-CoA carboxylase inhibitor and fibroblast growth factor 19 reduced tissue triglyceride content and fibrosis in human precision-cut liver slices
    Tsai, Wen-Wei
    Borthwick, Lee
    Mann, Jelena
    Bates, Jamie
    Trevaskis, James L.
    JOURNAL OF HEPATOLOGY, 2021, 75 : S614 - S614
12